05-08-2025
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.
